Results 61 to 70 of about 21,980 (135)

Neuro‐Immune Crosstalk: Molecular Mechanisms, Biological Functions, Diseases, and Therapeutic Targets

open access: yesMedComm, Volume 7, Issue 2, February 2026.
Neurons, immune cells, and other cellular components within the disease microenvironment (such as stromal cells and tumor cells) constitute a dynamically evolving ecosystem. Neurons directly modulate immune cell activity and inflammatory responses through the release of neurotransmitters (e.g., norepinephrine and CGRP), while also promoting tumor ...
Xin Guo   +11 more
wiley   +1 more source

Investigating the role of the PD-1 pathway in human ovarian cancer

open access: yes, 2010
Tumours have been shown to have a number of mechanisms to suppress immunosurveillance allowing them to survive and grow. One of these mechanisms involves expression of molecules which inhibit T cells such as the molecules involved in the PD-1 pathway. PD-
Maine, Christian, Maine, Christian
core   +1 more source

Regulation of PD-L1 expression in a high-grade invasive human oral squamous cell carcinoma microenvironment [PDF]

open access: yes, 2016
Blockade of the programmed-death 1 receptor (PD-1)/programmed-death ligand (PD-L1) pathway efficiently reduces tumour growth and improves survival. Durable tumour regression with blockade of the PD-1/PD-L1 checkpoint has been demonstrated in recent ...
Bou-Gharios, George   +6 more
core   +1 more source

Immunotherapy: is a minor god yet in the pantheon of treatments for lung cancer? [PDF]

open access: yes, 2014
Immunotherapy has been studied for many years in lung cancer without significant results, making the majority of oncologists quite skeptical about its possible application for non-small cell lung cancer treatment.
Annelies Janssens   +52 more
core   +1 more source

Potentiation of therapeutic immune responses against malignancies with monoclonal antibodies [PDF]

open access: yes, 2003
Immunotherapeutic monoclonal antibodies (mAbs) can be defined as those that exert their functions by tampering with immune system cell molecules, causing an enhancement of antitumor immune responses. Some of these antibodies are agonistic ligands for
Alfaro, C. (Carlos)   +9 more
core  

On the same side: VISTA and its ligands interact in cis on the cell surface

open access: yesProtein Science, Volume 35, Issue 1, January 2026.
Abstract VISTA, an essential immune checkpoint protein, regulates peripheral T‐cell quiescence and tolerance. Despite its potential as a target for anti‐tumor and autoimmune disease therapies, uncertainty regarding VISTA's binding mode and membrane orientation has hindered the development of these therapies.
Karina Smorodinsky‐Atias   +7 more
wiley   +1 more source

Expression of the costimulatory molecule B7-H3 is associated with prolonged survival in human pancreatic cancer [PDF]

open access: yes, 2009
Background Costimulatory signaling has been implicated as a potential regulator of antitumor immunity in various human cancers. In contrast to the negative prognostic value of aberrant B7-H1 expression by pancreatic cancer cells, the role of B7-H3 is ...
Kleeff Jörg   +7 more
core   +1 more source

Asthma in Patients With Confirmed Pulmonary Sarcoidosis

open access: yesCanadian Respiratory Journal, Volume 2026, Issue 1, 2026.
Pulmonary sarcoidosis and asthma can present identical symptoms, making clinical evaluation difficult if the two diseases overlap. Diagnostic challenges often lead to either overdiagnosis of asthma in patients with confirmed sarcoidosis or withholding appropriate asthma treatment.
Agata Anna Lewandowska   +9 more
wiley   +1 more source

Cancer Immunotherapy: a Review [PDF]

open access: yes, 2016
BACKGROUND: The goals of treating patients with cancer are to cure the disease, prolong survival, and improve quality of life. Immune cells in the tumor microenvironment have an important role in regulating tumor progression.
Dewi, N. M. (Nurrani)   +2 more
core   +3 more sources

Next‐Generation Immune Checkpoints and Tumor Microenvironment Modulation in Cancer Immunotherapy

open access: yesJournal of Immunology Research, Volume 2026, Issue 1, 2026.
Immunotherapy has reshaped the oncology landscape by enabling the immune system to recognize and eliminate malignant cells. Although immune checkpoint inhibitors (ICIs) targeting cytotoxic T‐lymphocyte‐associated protein 4 (CTLA‐4), programmed cell death‐1 (PD‐1), and programmed death‐ligand 1 (PD‐L1) have achieved durable responses in several cancers,
Jhommara Bautista   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy